Prelude Therapeutics (PRLD) Revenue & Revenue Breakdown
Prelude Therapeutics Revenue Highlights
00
Prelude Therapeutics Revenue by Period
Prelude Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Prelude Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $3.42M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Prelude Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KYMR | Kymera Therapeutics | $78.59M | $3.74M |
NRIX | Nurix Therapeutics | $76.99M | $12.59M |
FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
RVMD | Revolution Medicines | $11.58M | - |
MOLN | Molecular Partners | $7.04M | $2.74M |
STTK | Shattuck Labs | $1.66M | $1.61M |
RZLT | Rezolute | - | - |
BDTX | Black Diamond Therapeutics | - | - |
CCCC | C4 Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
PHVS | Pharvaris | - | - |
PASG | Passage Bio | - | - |
PRLD | Prelude Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
PEPG | PepGen | - | - |